CHOLANGIOCARCINOMA
Clinical trials for CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for advanced gut cancers? early trial tests targeted antibody
Disease control CompletedThis early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: Arbele Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Targeted drug shows promise for rare bile duct cancer
Disease control CompletedThis study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). Participants had already tried chemotherapy without success. The goal was to see if the drug could shrink tumors. Results help determ…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug targets rare gene mutations in advanced cancers
Disease control CompletedThis phase II trial tested the drug infigratinib in 17 adults with advanced or metastatic solid tumors that have specific FGFR gene mutations. The drug works by blocking overactive FGFR proteins that help cancer grow. The study measured how many patients' tumors shrank or stabili…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Sameek Roychowdhury • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill targets genetic flaw in tough cancers
Disease control CompletedThis early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New device combo for liver chemotherapy shows promise in small trial
Disease control CompletedThis study tested whether a Medtronic pump and Codman catheter can safely deliver chemotherapy directly to the liver in 35 people with colorectal cancer or bile duct cancer that spread to the liver. The main goal was to check safety, including liver side effects and need for sten…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cocktail of drugs shows early promise against tough bile duct cancer
Disease control CompletedThis phase 2 trial tested a combination of three drugs—chemotherapy delivered directly to the liver, a targeted pill, and an immunotherapy—in 25 people with advanced bile duct cancer that could not be removed surgically. The goal was to see if the combination could shrink tumors …
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
Which biopsy method best spots bile duct cancer?
Diagnosis CompletedThis study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…
Matched conditions: CHOLANGIOCARCINOMA
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New blood test could spare bile duct cancer patients unnecessary surgery
Diagnosis CompletedThis study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230…
Matched conditions: CHOLANGIOCARCINOMA
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
Which biopsy is best for hilar cancer? new study aims to find out
Diagnosis CompletedThis study compares two ways to get tissue samples from a suspected hilar bile duct cancer: one using an endoscope with ultrasound guidance (EUS-FNA/B) and another using a scope to look directly into the bile ducts (ERCP with or without a special camera). Researchers will check w…
Matched conditions: CHOLANGIOCARCINOMA
Sponsor: Qilu Hospital of Shandong University • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis CompletedThis study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Mindfulness may ease stress for liver patients
Symptom relief CompletedThis study looked at whether mindfulness exercises can lower stress and improve communication between patients with liver disease and their doctors. 56 adults took part, answering surveys about their stress, anxiety, and how well they felt they could share decisions with their he…
Matched conditions: CHOLANGIOCARCINOMA
Sponsor: Methodist Health System • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a palliative care team boost quality of life for cancer surgery patients?
Symptom relief CompletedThis study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…
Matched conditions: CHOLANGIOCARCINOMA
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Matched conditions: CHOLANGIOCARCINOMA
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Cancer patients may not need lifelong immunotherapy, study suggests
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…
Matched conditions: CHOLANGIOCARCINOMA
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New biopsy needle tested in 183 patients
Knowledge-focused CompletedThis study tested the EchoTip AcuCore, a needle used during endoscopic ultrasound to collect tissue samples from the pancreas, liver, and other organs. 183 adults with conditions like cancer or chronic pancreatitis took part. The main goal was to see if the needle could get a goo…
Matched conditions: CHOLANGIOCARCINOMA
Sponsor: Cook Research Incorporated • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC